18 and older, any sex, with Recurrent Diffuse Large B-Cell Lymphoma or Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response RatePrimary· 24 weeks
Number of patients achieving overall response rate
Group
Value
95% CI
Diffuse Large B-cell Lymphoma (DLBCL)
1
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
1
Diffuse Large B-cell Lymphoma (DLBCL)
3
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
1
Diffuse Large B-cell Lymphoma (DLBCL)
5
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
3
Diffuse Large B-cell Lymphoma (DLBCL)
34
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
7
Overall Survival (OS)Secondary· From the date of start of treatment to date of death due to any cause, assessed up to 60 months
The Kaplan-Meier method will be used to estimate the median OS time and its 95% CI.
Group
Value
95% CI
Diffuse Large B-cell Lymphoma (DLBCL)
5.9
3.3 – 14.3
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
6.9
3.8 – 24.3
Progression-free SurvivalSecondary· From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months.
The Kaplan-Meier method will be used to estimate the median PFS time and its 95% CI.
Group
Value
95% CI
Diffuse Large B-cell Lymphoma (DLBCL)
1.8
1.1 – 1.8
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
2.2
0.9 – 4.6
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Event monitoring should be continued for at least 30 days following the last dose of study treatment. Since this treatment trial was for relapsed or refractory disease in subjects, subjects were allowed to continue study treatment as long as they received benefit and met not reason for study discontinuation. The last subject remained on treatment for 7 1/2 years..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Diffuse Large B-cell Lymphoma (DLBCL)
Serious: 22/47 (47%)
Deaths: 31/47
Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)
Serious: 7/13 (54%)
Deaths: 11/13
Serious adverse events (58 terms)
Reaction
System
Diffuse Large B-cell Lymph…
Peripheral T-cell Non-Hodg…
Fever
General disorders
—
—
sepsis
Infections and infestations
—
—
thromboembolic event
Vascular disorders
—
—
Anemia
Blood and lymphatic system disorders
—
—
lung infection
Infections and infestations
—
—
hypoxia
Respiratory, thoracic and mediastinal disorders
—
—
Acute kidney injury
Injury, poisoning and procedural complications
—
—
dyspnea
Respiratory, thoracic and mediastinal disorders
—
—
hypercalcemia
Metabolism and nutrition disorders
—
—
ileus
Gastrointestinal disorders
—
—
respiratory failure
Respiratory, thoracic and mediastinal disorders
—
—
sinus tachycardia
Cardiac disorders
—
—
Infections and infestiations - Other
Infections and infestations
—
—
Respiratory disorder- other
Respiratory, thoracic and mediastinal disorders
—
—
cough
Respiratory, thoracic and mediastinal disorders
—
—
Fall
Injury, poisoning and procedural complications
—
—
fatigue
General disorders
—
—
febrile neutropenia
Blood and lymphatic system disorders
—
—
hypernatremia
Metabolism and nutrition disorders
—
—
hyponatremia
Metabolism and nutrition disorders
—
—
hypophosphatemia
Metabolism and nutrition disorders
—
—
hypotension
Vascular disorders
—
—
Injury, procedural - Other
Injury, poisoning and procedural complications
—
—
Musculoskeletal, Other
Musculoskeletal and connective tissue disorders
—
—
pleuritc pain
Respiratory, thoracic and mediastinal disorders
—
—
Other adverse events (23 terms — click to expand)
Reaction
System
Diffuse Large B-cell Lymph…
Peripheral T-cell Non-Hodg…
anemia
Blood and lymphatic system disorders
—
—
platelet count decreased
Investigations
—
—
lymphocyte count decreased
Investigations
—
—
dyspnea
Respiratory, thoracic and mediastinal disorders
—
—
neutrophil count decreased
Investigations
—
—
sepsis
Infections and infestations
—
—
fatigue
General disorders
—
—
hyponatremia
Metabolism and nutrition disorders
—
—
fever
General disorders
—
—
hypercalcemia
Metabolism and nutrition disorders
—
—
hypophosphatemia
Metabolism and nutrition disorders
—
—
hypotension
Vascular disorders
—
—
Respiratory, thoracic and mediastinal disorder - Other
This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
· withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men
· withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance
· Phase 1, PHASE2
· recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
· Phase 1
· active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
· Phase 1
· active not recruiting
Other recruiting trials for Recurrent Diffuse Large B-Cell Lymphoma
Currently open trials in the same condition.
NCT07042438 — Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo
· Phase 2
· recruiting
NCT06859008 — Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
· Phase 1
· recruiting
NCT07098364 — ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
· Phase 1, PHASE2
· recruiting
NCT06649812 — Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
· Phase 2
· recruiting
NCT06784726 — Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
· Phase 2
· recruiting
Other University of Nebraska trials
Trials by the same sponsor.
NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance
· NA
· not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
· NA
· not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments
· not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation
· NA
· not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
· Phase 2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 5 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01431209.